肿瘤空间异质性影像学定量评价进展

doi:10.3760/cma.j.issn.1004-4221.2017.12.021

Abstract
Figure/Table
References()
Related Citation (3)
Read Tracking
Download Tracking

Download: PDF (852 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Tumor heterogeneity is characteristic in malignant tumors. It is a new challenge in imageology to achieve the visualization of tumor heterogeneity and precise quantification using modern imaging techniques. To solve this problem, the newly emerging radiomics is applied to analyze tumor spatial heterogeneity, with a visualization effect. Image quantification methods, including histogram analysis, texture analysis, and parametric response mapping, can accelerate the research and development of new drugs, improve the efficacy prediction, modify the treatment regimen, and promote the prognostic evaluation.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Siying
	Chen Feng

Key words： Tumor spatial heterogeneity Radiomics Histogram analysis Texture analysis Parametric response map

Received: 20 December 2016

Fund:

Projects supported by National Natural Science Foundation of China (30670603);Zhejiang Provincial Commission for Health Planning (2014PYA009)

Corresponding Authors: Chen Feng,Email:chenfenghz@zju.edu.cn

Cite this article:

Zhang Siying,Chen Feng. Progress in quantitative imaging evaluation of tumor spatial heterogeneity[J]. Chinese Journal of Radiation Oncology, 2017, 26(12): 1451-1456.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.12.021 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I12/1451

[1] Bedard PL,Hansen AR,Ratain MJ,et al. Tumour heterogeneity in the clinic[J].Nature,2013,501(7467):355-364.DOI:10.1038/nature12627.
[2] Meacham CE,Morrison SJ.Tumour heterogeneity and cancer cell plasticity[J].Nature,2013,501(7467):328-337.DOI:10.1038/nature12624.
[3] Robinson S P,Mcintyre D J,Checkley D,et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging[J].Br J Cancer,2003,88(10):1592-1597.DOI:10.1038/sj.bjc.6600926.
[4] Just N.Improving tumour heterogeneity MRI assessment with histograms[J].Br J Cancer,2014,111(12):2205-2213.DOI:10.1038/bjc.2014.512.
[5] De Sousa Melo F,Vermeulen L,Fessler E,et al. Cancer heterogeneity:a multifaceted view[J].EMBO Reports,2013,14(8):686-695.DOI:10.1038/embor.2013.92.
[6] Davnall F,Yip CSP,Ljungqvist G,et al. Assessment of tumor heterogeneity:an emerging imaging tool for clinical practice?[J].Insight Imag,2012,3(6):573-589.DOI:10.1007/s13244-012-0196-6.
[7] O'Connor JPB,Rose CJ,Waterton JC,et al. Imaging Intratumor Heterogeneity:Role in Therapy Response,Resistance,and Clinical Outcome[J].Clin Cancer Res,2015,21(2):249-257.DOI:10.1158/1078-0432.
[8] Bull J G,Saunders D E,Clark C A.Discrimination of paediatric brain tumours using apparent diffusion coefficient histograms[J].Eur Radiol,2012,22(2):447-457.DOI:10.1007/s00330-011-2255-7.
[9] Song YS,Choi SH,Park CK,et al. True progression versus pseudoprogression in the treatment of glioblastomas:a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis[J].Kor J Radiol,2013,14(4):662-672.DOI:10.3348/kjr.2013.14.4.662.
[10] Kim H,Choi SH,Kim JH,et al. Gliomas:application of cumulative histogram analysis of normalized cerebral blood volume on 3 T MRI to tumor grading[J].PLoS One,2013,8(5):e63462.DOI:10.1371/journal.pone.0063462.
[11] Chandarana H,Rosenkrantz AB,Mussi TC,et al. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer[J].Radiology,2012,265(3):790-798.DOI:10.1148/radiol.12111281.
[12] Downey K,Riches SF,Morgan VA,et al. Relationship between imaging biomarkers of stage Ⅰ cervical cancer and poor-prognosis histologic features:quantitative histogram analysis of diffusion-weighted MR images[J].AJR Am J Roentgenol,2013,200(2):314-320.DOI:10.2214/AJR.12.9545.
[13] Woo S,Cho JY,Kim SY,et al. Histogram analysis of apparent diffusion coefficient map of diffusion-weighted MRI in endometrial cancer:a preliminary correlation study with histological grade[J].Acta Radiol,2014,55(10):1270-1277.DOI:10.1177/0284185113514967.
[14] Baek H J,Kim H S,Kim N,et al. Percent change of perfusion skewness and kurtosis:a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas[J].Radiology,2012,264(3):834-843.DOI:10.1148/radiol.12112120.
[15] King AD,Chow KK,Yu KH,et al. Head and neck squamous cell carcinoma:diagnostic performance of diffusion-weighted MR imaging for the prediction of treatment response[J].Radiology,2013,266(2):531-538.DOI:10.1148/radiol.12120167.
[16] Johansen R,Jensen LR,Rydland J,et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI[J].J Magnet Reson Imag,2009,29(6):1300-1307.DOI:10.1002/jmri.21778.
[17] Chang YC,Huang CS,Liu YJ,et al. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI[J].Phys Med Biol,2004,49(16):3593-3602.DOI:10.1088/0031-9155/49/16/007.
[18] Kyriazi S,Collins DJ,Messiou C,et al. Metastatic ovarian and primary peritoneal cancer:assessing chemotherapy response with diffusion-weighted MR imaging—value of histogram analysis of apparent diffusion coefficients[J].Radiology,2011,261(1):182-192.DOI:10.1148/radiol.11110577.
[19] Yuh WTC,Mayr NA,Jarjoura D,et al. Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer[J].Investigative Radiology,2009,44(6):343-350.DOI:10.1097/RLI.0b013e3181a64ce9.
[20] Castellano G,Bonilha L,Li LM,et al. Texture analysis of medical images[J].Clin Radiol,2004,59(12):1061-1069.DOI:10.1016/j.crad.2004.07.008.
[21] Nielsen B,Albregtsen F,Danielsen HE.Statistical nuclear texture analysis in cancer research:a review of methods and applications[J].Crit Revi Oncogen,2008,14(2-3):89-164.DOI:10.1615/CritRevOncog.v14.i2-3.10.
[22] Haralick RM.Statistical and structural approaches to texture[J].Proceedings of the IEEE,1979,67(5):786-804.DOI:10.1109/PROC.1979.11328.
[23] Michallek F,Dewey M.Fractal analysis in radiological and nuclear medicine perfusion imaging:a systematic review[J].Eur Radiol,2014,24(1):60-69.DOI:10.1007/s00330-013-2977-9.
[24] Molina D,Pérez-Beteta J,Luque B,et al. Tumour heterogeneity in glioblastoma assessed by MRI texture analysis:a potential marker of survival[J].Br J Radiol,2016,4:20160242.DOI:10.1259/bjr.20160242.
[25] Eliat P,Olivié D,Skali S,et al. Can dynamic contrast-enhanced magnetic resonance imaging combined with texture analysis differentiate malignant glioneuronal tumors from other Glioblastoma?[J].Neurol Res Int,2012,2012:195176.DOI:10.1155/2012/195176.
[26] Holli K,Lääperi A L,Harrison L,et al. Characterization of breast cancer types by texture analysis of magnetic resonance images[J].Academ Radiol,2010,17(2):135-141.DOI:10.1016/j.acra.2009.08.012.
[27] Schieda N,Thornhill R E,Al-Subhi M,et al. Diagnosis of sarcomatoid renal cell carcinoma With CT:evaluation by qualitative imaging features and texture analysis[J].AJR Am J Roentgenol,2015,204(5):1013-1023.DOI:10.2214/AJR.14.13279.
[28] Kido S,Kuriyama K,Higashiyama M,et al. Fractal analysis of small peripheral pulmonary nodules in thin-section CT:evaluation of the lung-nodule interfaces[J].J Comput Assist Tomogr,2002,26(4):573-578.DOI:10.1097/00004728-200207000-00017.
[29] Lopes R,Ayache A,Makni N,et al. Prostate cancer characterization on MR images using fractal features[J].Med Phys,2011,38(1):83-95.DOI:10.1118/1.3521470.
[30] Goh V,Ganeshan B,Nathan P,et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer:CT texture as a predictive biomarker[J].Radiology,2011,261(1):165-171.DOI:10.1148/radiol.11110264.
[31] Ng F,Ganeshan B,Kozarski R,et al. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis:contrast-enhanced CT texture as a biomarker of 5-year survival[J].Radiology,2013,266(1):177-184.DOI:10.1148/radiol.12120254.
[32] Balagurunathan Y,Gu YH,Wang H,et al. Reproducibility and prognosis of quantitative features extracted from CT images[J].Transl Oncol,2014,7(1):72-87.DOI:10.1593/tlo.13844.
[33] Lee J,Jain R,Khalil K,et al. Texture feature ratios from relative CBV maps of perfusion MRI are associated with patient survival in Glioblastoma[J].Am J Neuroradiol,2016,37(1):37-43.DOI:10.3174/ajnr. A4534.
[34] Kim JH,Ko ES,Lim Y,et al. Breast cancer heterogeneity:MR imaging texture analysis and survival outcomes[J].Radiology,2016,282(3):160261.DOI:10.1148/radiol.2016160261.
[35] O'Connor JP,Rose CJ,Jackson A,et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6[J].Br J Cancer,2011,105(1):139-145.DOI:10.1038/bjc.2011.191.
[36] Alic L,Van Vliet M,Van Dijke CF,et al. Heterogeneity in DCE-MRI parametric maps:a biomarker for treatment response?[J].Phys Med Biol,2011,56(6):1601-1616.DOI:10.1088/0031-9155/56/6/006.
[37] Moffat BA,Chenevert TL,Lawrence TS,et al. Functional diffusion map:a noninvasive MRI biomarker for early stratification of clinical brain tumor response[J].Proc Natl Acad Sci U S A,2005,102(15):5524-5529.DOI:10.1073/pnas.0501532102.
[38] Galbán CJ,Chenevert TL,Meyer CR,et al. Prospective analysis of parametric response map-derived MRI biomarkers:identification of early and distinct Glioma response patterns not predicted by standard radiographic assessment[J].Clin Cancer Res,2011,17(14):4751-4760.DOI:10.1158/1078-0432.
[39] Galbán CJ,Chenevert TL,Meyer CR,et al. The parametric response map is an imaging biomarker for early cancer treatment outcome[J].Nat Med,2009,15(5):572-576.DOI:10.1038/nm.1919.
[40] Hamstra DA,Chenevert TL,Moffat BA,et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma[J].Proc Natl Acad Sci USA,2005,102(46):16759-16764.DOI:10.1073/pnas.0508347102.
[41] Ellingson BM,Malkin MG,Rand SD,et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity[J].J Magn Reson Imag,2010,31(3):538-548.DOI:10.1002/jmri.22068.
[42] Cho N,Im SA,Park IA,et al. Breast cancer:early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging[J].Radiology,2014,272(2):385-396.DOI:10.1148/radiol.14131332.
[43] Lee KC,Bradley DA,Hussain M,et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone[J].Neoplasia,2007,9(12):1003-1011.DOI:10.1593/neo.07954.
[44] Galbán CJ,Mukherji SK,Chenevert TL,et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy[J].Transl Oncol,2009,2(3):184-190.DOI:10.1593/tlo.09175.
[45] Ceschin R,Kurland BF,Abberbock SR,et al. Parametric response mapping of apparent diffusion coefficient as an imaging biomarker to distinguish pseudoprogression from true tumor progression in peptide-based vaccine therapy for pediatric diffuse intrinsic pontine Glioma[J].Am J Neuroradiol,2015,36(11):2170-2176.DOI:10.3174/ajnr. A4428.
[46] Lambin P,Rios-Velazquez E,Leijenaar R,et al. Radiomics:extracting more information from medical images using advanced feature analysis[J].Eur J Cancer,2012,48(4):441-446.DOI:10.1016/j.ejca.2011.11.036.
[47] Kumar V,Gu YH,Basu S,et al. Radiomics:the process and the challenges[J].Magn Reson Imag,2012,30(9):1234-1248.DOI:10.1016/j.mri.2012.06.010.
[48] Aerts HJWL,Velazquez ER,Leijenaar RTH,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach[J].Nat Commun,2014,5:4006.DOI:10.1038/ncomms5006.
[49] Huang YQ,Liang CH,He L,et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer[J].J Clin Oncol,2016,34(18):2157-2164.DOI:10.1200/JCO.2015.65.9128.
[50] Zhou Y,He L,Huang YQ,et al. CT-based radiomics signature:a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma[J].Abdom Radiol (NY),2017,42(6):1695-1704.DOI:10.1007/s00261-017-1072-0.
[51] Huang YQ,Liu ZY,He L,et al. Radiomics signature:a potential biomarker for the prediction of disease-free survival in early-stage (I or Ⅱ) non-small cell lung cancer[J].Radiology,2016,281(3):947-957.DOI:10.1148/radiol.2016152234.